Exact Sciences stock edges higher on Q2 2026 growth

Published on 09/11/2026 at 15:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exact Sciences stock closed on the Nasdaq at a moderate distance below its 52-week high on September 9, 2026. Q2 2026 revenue rose double digits and guidance was refined.

Wissenschaftlerinnen analysieren Krebsproben in einem modernen Diagnostiklabor von Exact Sciences — Exact Sciences Corp. betreibt hochmoderne Labore für die molekulare Krebsfrüherkennung weltweit ISIN US30063P1057, Illustration mit AI erstellt.

Exact Sciences stock (US30063P1057) closed on the Nasdaq at a moderate distance below its 52-week high on September 9, 2026, while the latest Q2 2026 update pointed to double-digit revenue growth and a narrower loss target.

Q2 growth stays visible

According to ad hoc news on September 10, 2026, Exact Sciences said Q2 2026 revenue increased compared with the prior-year period, with the quarter showing double-digit year-over-year growth. The same update says management refined full-year guidance and still expects continued revenue growth in 2026.

The earnings update also tied the improvement to continued Cologuard adoption and growth in precision oncology testing. That matters for investors because the market is still weighing growth against profitability, reimbursement pressure and competition.

Price sits in range

As of September 9, 2026, the shares closed on the Nasdaq between their 52-week high and 52-week low, according to ad hoc news. The same source says trading volume was in line with recent averages and market capitalization remained in the mid-cap biotech and diagnostics range.

On the same Q2 2026 backdrop, the stock was described as moderately below its 52-week high, which suggests the market is still crediting the growth story while keeping a discount on execution risk.

What investors watch

The current debate is simple: whether double-digit Q2 2026 growth can keep offsetting the drag from margin pressure and reimbursement risk. For Exact Sciences, the next move in sentiment will likely come from the pace of revenue growth and any further guidance updates.

Nasdaq close level

Exact Sciences stock ended at a level reported for September 9, 2026, on the Nasdaq, with the latest market read still centered on the Q2 2026 update and the refined 2026 outlook.